| Q59812993 | A Novel Cellular Pathway of Antigen Presentation and CD4 T Cell Activation |
| Q38098855 | A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant |
| Q35208463 | A micro-sterile inflammation array as an adjuvant for influenza vaccines |
| Q92597111 | Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity |
| Q36538834 | Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine Immunity |
| Q57094841 | Adjuvanted influenza vaccines |
| Q38520210 | Adjuvants in micro- to nanoscale: current state and future direction |
| Q35826747 | Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators |
| Q26747586 | Adjuvants: Classification, Modus Operandi, and Licensing |
| Q27007659 | Advances in aluminum hydroxide-based adjuvant research and its mechanism |
| Q29248341 | Allergic Responses Induced by the Immunomodulatory Effects of Nanomaterials upon Skin Exposure |
| Q36714911 | Alum Directly Modulates Murine B Lymphocytes to Produce IgG1 Isotype |
| Q26752643 | Alum: an old dog with new tricks |
| Q34990010 | Aluminum hydroxide adjuvant differentially activates the three complement pathways with major involvement of the alternative pathway |
| Q27687250 | Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases |
| Q90398348 | Better Adjuvants for Better Vaccines: Progress in Adjuvant Delivery Systems, Modifications, and Adjuvant-Antigen Codelivery |
| Q36618500 | Beyond antigens and adjuvants: formulating future vaccines |
| Q57480337 | Biomaterials for vaccine-based cancer immunotherapy |
| Q21129422 | Biopersistence and brain translocation of aluminum adjuvants of vaccines |
| Q38761412 | Clinical use of adjuvants in allergen-immunotherapy. |
| Q37539243 | Co-Administration of Lipid Nanoparticles and Sub-Unit Vaccine Antigens Is Required for Increase in Antigen-Specific Immune Responses in Mice |
| Q37153656 | Contamination of DNase Preparations Confounds Analysis of the Role of DNA in Alum-Adjuvanted Vaccines |
| Q40077299 | Dendritic cell and antigen dispersal landscapes regulate T cell immunity |
| Q93338385 | Dendritic cell subsets in T cell programming: location dictates function |
| Q35549338 | Effective and lesion-free cutaneous influenza vaccination |
| Q38154804 | Engineering synthetic vaccines using cues from natural immunity |
| Q42049992 | Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation |
| Q39454581 | Germinal center enhancement by extended antigen availability |
| Q93374969 | Heat shock proteins: A dual carrier-adjuvant for an anti-drug vaccine against heroin |
| Q41842923 | IL-33 released by alum is responsible for early cytokine production and has adjuvant properties |
| Q91899715 | Imaging the early fate of mRNA vaccines |
| Q28972540 | Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands |
| Q37516206 | Immunization of rhesus macaques with Echinococcus multilocularis recombinant 14-3-3 antigen leads to specific antibody response |
| Q34976001 | Increasing the potency of an alhydrogel-formulated anthrax vaccine by minimizing antigen-adjuvant interactions |
| Q35053924 | Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy. |
| Q51697509 | Interleukin-4- and NACHT, LRR and PYD domains-containing protein 3-independent mechanisms of alum enhanced T helper type 2 responses on basophils. |
| Q38032881 | Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines |
| Q28079872 | Local innate immune responses in the vaccine adjuvant-injected muscle |
| Q42036323 | Mechanism of immunopotentiation and safety of aluminum adjuvants. |
| Q38110539 | Mechanisms of action of adjuvants |
| Q51336724 | Modulation of Immune Responses by Particulate Materials. |
| Q30389181 | Natural STING Agonist as an "Ideal" Adjuvant for Cutaneous Vaccination. |
| Q47161651 | Neutrophil swarming and extracellular trap formation play a significant role in Alum adjuvant activity. |
| Q92646889 | New Insights on the Adjuvant Properties of the Leishmania infantum Eukaryotic Initiation Factor |
| Q30418570 | Novel viral vectored vaccines for the prevention of influenza |
| Q57478910 | Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want |
| Q36784106 | Particulate adjuvant and innate immunity: past achievements, present findings, and future prospects |
| Q38286377 | Particulate inorganic adjuvants: recent developments and future outlook |
| Q88333970 | Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8+ T Cell Response |
| Q33710195 | Polyanhydride Nanovaccines Induce Germinal Center B Cell Formation and Sustained Serum Antibody Responses |
| Q26852816 | Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes |
| Q35664854 | Properties and prospects of adjuvants in influenza vaccination - messy precipitates or blessed opportunities? |
| Q33912121 | Protein coated microcrystals formulated with model antigens and modified with calcium phosphate exhibit enhanced phagocytosis and immunogenicity |
| Q28083679 | Recent advances of vaccine adjuvants for infectious diseases |
| Q60921906 | Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technology |
| Q38907063 | Retention of Ag-specific memory CD4+ T cells in the draining lymph node indicates lymphoid tissue resident memory populations |
| Q47123344 | Sequestering of damage-associated molecular patterns (DAMPs): a possible mechanism affecting the immune-stimulating properties of aluminium adjuvants |
| Q53080536 | Soluble antigen traffics rapidly and selectively from the corneal surface to the eye draining lymph node and activates T cells when codelivered with CpG oligonucleotides. |
| Q64071684 | Spatiotemporal Modeling of the Key Migratory Events During the Initiation of Adaptive Immunity |
| Q36356773 | Suppression of established hepatocarcinoma in adjuvant only immunotherapy: alum triggers anti-tumor CD8+ T cell response |
| Q37379662 | Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination |
| Q38072067 | Synthetic adjuvants for vaccine formulations: phytol derivatives |
| Q55216329 | Systematic Overview of Solid Particles and Their Host Responses. |
| Q28387541 | Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts |
| Q100466517 | Technological approaches to streamline vaccination schedules, progressing towards single-dose vaccines |
| Q45831503 | Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants |
| Q36599857 | The TLR2/6 ligand PAM2CSK4 is a Th2 polarizing adjuvant in Leishmania major and Brugia malayi murine vaccine models. |
| Q33909251 | The dichotomy of pathogens and allergens in vaccination approaches |
| Q38453147 | The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm. |
| Q54498522 | The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses. |
| Q48316344 | Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform |
| Q94318796 | Understanding the Localization of Berylliosis: Interaction of Be2+ with Carbohydrates and Related Biomimetic Ligands |
| Q50046250 | Uric acid and the vaccine adjuvant activity of aluminium (oxy)hydroxide nanoparticles. |
| Q26752522 | Vaccine adjuvants as potential cancer immunotherapeutics |
| Q91705195 | Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity |
| Q21131210 | Vaccine adjuvants: mode of action |
| Q89934844 | [Adjuvants] |